Although immunohistochemical PD-L1 expression in NSCLC is a predictive biomarker of response to PD-1/PD-L1-inhibiting mAbs, other potential predictive biomarkers such as PD-1 expression in tumor-infiltrating lymphocytes (TILs) or the ability of the PD-1 antibody to reach its target have not been evaluated (5). This evidence concerns the gene CD274 and non-small cell lung carcinoma.